Nectar Lifesciences growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−100.0%−0.7%+10.6%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−129.4%−117.3%+183.8%
+31.3%−196.2%+1,886.1%
−157.6%−2,376.1%+120.7%
−164.3%−2,404.5%+120.4%
−69.6%−6.6%+0.1%
−39.1%−10.6%+0.4%
−305.8%−24.6%+68.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NECLIFE₹10.33

Nectar Lifesciences Limited

· Pharma & Health
₹ CrorePeersAAREYDRUGSNATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹201 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+10.6-0.7-100.0—
EBITDA Growth—+183.8-117.3-129.4—
EBIT Growth—+1,886.1-196.2+31.3—
Net Income Growth—+120.7-2,376.1-157.6—
EPS Growth—+120.4-2,404.5-164.3—
Total Assets Growth—+0.1-6.6-69.6—
Total Equity Growth—+0.4-10.6-39.1—
Cash from Operations Growth—+68.1-24.6-305.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.